Related Experiment Video
Updated: Apr 7, 2026

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
Published on: February 21, 2025
Intratumoral delivery of mRNA: Overcoming obstacles for effective immunotherapy
Kevin Van der Jeught1, Sandra Van Lint1, Kris Thielemans1
1Laboratory of Molecular and Cellular Therapy; Department of Biomedical Sciences; Vrije Universiteit Brussel ; Jette, Belgium.
Abstract:
The immunosuppressive tumor microenvironment (TME) is a major obstacle in cancer immunotherapy. Therefore, it has gained attention as a target site. mRNA emerged as a versatile drug class for cancer therapy. We reported that intratumoral administration of mRNA encoding the fusokine Fβ2 supports tumor-specific T-cell immunity. This study provides proof of concept of the use of mRNA to modulate the TME.

